Elon Musk GLP-1 Use Compared to Similar Public Figures

What Elon Musk Has Said About His GLP-1 Use

Musk confirmed his use of Wegovy in a reply on X in October 2022, stating the drug was effective for weight management. He also referenced fasting as part of his approach. The disclosure was brief: no dosing details, no timeline, no named prescriber. That terseness contrasts sharply with longer-form disclosures by other public figures.

The X Post That Started the Conversation

When a follower asked about his noticeably leaner appearance, Musk responded with a single word: "Wegovy." He later added that fasting helped. The casualness of the admission set the tone for a wave of celebrity GLP-1 disclosures that followed throughout 2023 and 2024.

What We Do Not Know

Musk has not shared his starting weight, target weight, maintenance dose, or whether he remains on semaglutide. He has not disclosed whether he uses the standard 2.4 mg maintenance dose or a lower titration step. Without those details, any claims about his specific weight loss percentage remain speculative. The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity recommends ongoing treatment for patients who respond to GLP-1 therapy, noting that weight regain is common after discontinuation 1.

Fasting as a Complement

Musk referenced intermittent fasting alongside Wegovy. A 2023 meta-analysis in JAMA Network Open found that intermittent fasting produced 1% to 8% body weight loss over 8 to 12 weeks, with the range depending on protocol intensity 2. Combining caloric restriction with a GLP-1 agonist is not uncommon in clinical practice, though the additive benefit has not been quantified in a dedicated randomized controlled trial.

The STEP Trial Data Behind Wegovy

Semaglutide 2.4 mg earned its FDA approval on the strength of the STEP trial program, one of the largest obesity pharmacotherapy datasets ever assembled. These numbers provide the clinical backdrop for evaluating any individual's results, including Musk's.

STEP-1 Results

In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg achieved a mean body weight reduction of 14.9% at 68 weeks, compared with 2.4% in the placebo group 3. About one-third of semaglutide-treated participants lost 20% or more of their body weight.

STEP-3 and Lifestyle Intensification

STEP-3 (N=611) added intensive behavioral therapy (a low-calorie diet for the first 8 weeks plus ongoing counseling) to semaglutide 2.4 mg. Participants lost 16.0% of body weight at 68 weeks versus 5.7% with placebo 4. Musk's addition of fasting loosely parallels the lifestyle-intensification arm, though his approach was self-directed.

Durability and the STEP-1 Extension

The STEP-1 trial extension showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year 5. This finding shapes the clinical calculus for every patient, celebrity or not. The American Association of Clinical Endocrinology (AACE) 2023 consensus statement describes obesity as a chronic disease requiring long-term pharmacotherapy in most responders 6.

Oprah Winfrey: The Most Detailed Public Disclosure

Oprah Winfrey disclosed her use of a GLP-1 medication in December 2023 during an interview, later clarifying on her special An Oprah Special: Shame, Blame, and the Weight Loss Revolution (March 2024). Her disclosure stands as the most detailed among celebrity users.

What Oprah Has Shared

Winfrey stated she uses a GLP-1 medication as a "maintenance tool" alongside exercise and a calorie-aware diet. She did not name the specific drug, though reporting by People and The New York Times pointed to semaglutide. She described years of public scrutiny over her weight, framing the medication as removing what she called "the brain noise" around food.

Clinical Framing

Dr. Amanda Velazquez, director of obesity medicine at Cedars-Sinai, has noted publicly: "GLP-1 receptor agonists work on the hypothalamic appetite centers. They reduce the constant food-seeking signals that patients with obesity describe. That is a neurobiological effect, not willpower" 7.

Comparison to Musk

Winfrey's disclosure was deliberate, emotional, and framed around decades of public weight stigma. Musk's was a one-word tweet. The clinical distinction matters less than the communication style: Winfrey's approach prompted a national conversation about obesity as a disease, while Musk's treated Wegovy as a consumer product recommendation. Both approaches normalized GLP-1 therapy, but through different cultural registers.

Sharon Osbourne: A Cautionary Counterpoint

Sharon Osbourne has been one of the most vocal celebrity critics of her own GLP-1 experience. She disclosed using Ozempic (semaglutide 1 mg, approved for type 2 diabetes rather than weight management) and described the results as excessive.

What Osbourne Reported

In multiple television interviews throughout 2023, Osbourne said she lost approximately 42 pounds and felt she had become "too thin." She described nausea, appetite suppression that made eating difficult, and a gaunt facial appearance sometimes called "Ozempic face."

The Gastrointestinal Side-Effect Profile

Osbourne's reported nausea aligns with established trial data. In STEP-1, nausea occurred in 44.2% of semaglutide-treated participants versus 17.4% on placebo 3. Most cases were mild to moderate and peaked during dose escalation. A 2023 pharmacovigilance analysis in JAMA identified signals for pancreatitis, gastroparesis, and bowel obstruction at rates exceeding background, though absolute risk remained low 8.

Why This Comparison Matters

Osbourne used the diabetes-indication formulation (Ozempic, max 2 mg) rather than the obesity-indication formulation (Wegovy, max 2.4 mg), and she reported no structured medical follow-up during dose escalation. Musk used the FDA-approved weight management product. This distinction underscores a point the AACE guidelines emphasize: GLP-1 therapy for obesity requires structured titration, regular follow-up, and dose adjustment based on tolerability and response 6.

Charles Barkley: Tirzepatide, Not Semaglutide

Charles Barkley disclosed in early 2024 that he was using Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, rather than a pure GLP-1 drug like Wegovy. He reported losing approximately 60 pounds.

A Different Mechanism

Tirzepatide activates both GLP-1 and GIP receptors. In the SURMOUNT-1 trial (N=2,539), participants receiving tirzepatide 15 mg lost a mean of 22.5% of body weight at 72 weeks versus 2.4% on placebo 9. That exceeds the 14.9% seen with semaglutide 2.4 mg in STEP-1, though head-to-head data between the two drugs at their weight-management doses are limited.

Barkley's Public Framing

Barkley discussed his GLP-1 use on multiple sports broadcasts and podcasts, treating it matter-of-factly. He mentioned that his doctor recommended tirzepatide because of his size (he played at 252 pounds during his NBA career) and metabolic risk profile. His approach shares Musk's informality but includes more clinical context, naming the prescriber relationship and the medical rationale.

Semaglutide Versus Tirzepatide: What the Data Shows

The SURPASS-2 trial (N=1,879) compared tirzepatide directly with semaglutide 1 mg in patients with type 2 diabetes. All three tirzepatide doses (5, 10, and 15 mg) produced greater HbA1c reductions than semaglutide 1 mg 10. Weight loss was also greater with tirzepatide at all doses. A direct comparison at the obesity-indication doses (semaglutide 2.4 mg versus tirzepatide 10 or 15 mg) has not yet been published in a randomized trial.

Other Notable Public Figure Disclosures

Several other high-profile individuals have publicly discussed GLP-1 use, creating a broader comparison field.

Tracy Morgan

The comedian disclosed Ozempic use in 2023, stating it helped him lose over 40 pounds. He later expressed concern about losing too much weight and described tapering off the drug, a sequence that mirrors the STEP-1 extension data on post-cessation regain 5.

Chelsea Handler

Handler said on the Call Her Daddy podcast that she was prescribed a GLP-1 agonist without fully understanding what it was. She later discontinued it after learning it was a diabetes medication being used off-label. Her case highlights the informed-consent gap that the FDA's 2023 Drug Safety Communication addressed, reminding prescribers to discuss the difference between approved and off-label indications 11.

The Pattern Across Disclosures

Among celebrity disclosers, a pattern emerges: men (Musk, Barkley, Morgan) tend toward brief, matter-of-fact confirmations. Women (Winfrey, Osbourne, Handler) tend to provide more emotional or narrative context. This pattern may reflect gendered differences in the social experience of weight stigma, which a 2022 study in Obesity found disproportionately affects women in public-facing roles 12.

What Clinicians Should Take From Celebrity GLP-1 Disclosures

Celebrity disclosures are not clinical data. They are, at best, anecdotes with large audiences. But they influence prescribing patterns and patient expectations in measurable ways.

The "Ozempic Effect" on Prescribing Volume

GLP-1 receptor agonist prescriptions for weight management increased by 300% between Q1 2022 and Q4 2023, according to IQVIA prescription data. Celebrity disclosures were not the sole driver, but temporal correlation with the Musk and Winfrey disclosures is visible in the data.

Patient Expectations Versus Trial Results

The AACE consensus statement notes that a 5% to 15% body weight reduction should be considered clinically meaningful, and patients should be counseled that results vary widely 6. Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine and co-author of the STEP-3 protocol, has stated: "When patients come in asking for 'the Ozempic,' they often expect the best-case scenario. Our job is to set realistic targets based on their BMI, comorbidities, and adherence capacity" 13.

Titration and Monitoring Remain Non-Negotiable

Across every celebrity disclosure reviewed here, the ones associated with adverse outcomes (Osbourne's excessive weight loss, Morgan's rebound, Handler's uninformed prescribing) involved inadequate titration or follow-up. The FDA-approved Wegovy titration schedule calls for 16 weeks of dose escalation (0.25 mg to 0.5 mg to 1 mg to 1.7 mg to 2.4 mg) before reaching the maintenance dose 11. Skipping steps or prescribing without ongoing monitoring correlates with the side-effect profiles these public figures described.

Where Musk Fits in the Broader GLP-1 Field

Musk's GLP-1 disclosure is neither the most informative nor the most influential on its own. Its significance lies in timing and reach. He confirmed Wegovy use when the drug was still relatively unknown outside endocrinology circles, and his X platform gave the post an audience of tens of millions.

A Comparison Table

| Figure | Drug | Mechanism | Reported Loss | Disclosure Style | |---|---|---|---|---| | Elon Musk | Wegovy (semaglutide 2.4 mg) | GLP-1 RA | Not quantified | One-word tweet | | Oprah Winfrey | GLP-1 (likely semaglutide) | GLP-1 RA | Not quantified | TV special, interviews | | Sharon Osbourne | Ozempic (semaglutide 1 mg) | GLP-1 RA | ~42 lbs | TV interviews, expressed regret | | Charles Barkley | Mounjaro (tirzepatide) | Dual GIP/GLP-1 | ~60 lbs | Sports broadcasts | | Tracy Morgan | Ozempic (semaglutide) | GLP-1 RA | ~40 lbs | Interviews, later tapered | | Chelsea Handler | GLP-1 (unspecified) | GLP-1 RA | Not quantified | Podcast, later discontinued |

The Clinical Takeaway

Celebrity disclosures do not change the pharmacology. Semaglutide 2.4 mg produces a mean weight loss of 14.9% at 68 weeks in clinical trials 3. Tirzepatide 15 mg produces 22.5% at 72 weeks 9. Individual results depend on baseline BMI, adherence, concurrent lifestyle changes, and genetic variation in GLP-1 receptor sensitivity. Patients considering GLP-1 therapy should discuss eligibility criteria (BMI of 30 or greater, or 27 or greater with a weight-related comorbidity) and the 16-week titration schedule with a board-certified clinician before starting treatment.